Dihexa
Experimental nootropic; Preclinical evidence with research-integrity cautions
Brief Overview: Dihexa is a synthetic angiotensin-IV-derived compound marketed as a cognitive and neurorepair peptide. For a beginner, the key point is that it is not an approved medicine and not a clinically validated nootropic. It is better understood as a research compound with interesting preclinical signals and unusually large uncertainty. Evidence lens: The strongest claims for Dihexa came from preclinical work, not human trials. A central HGF/c-Met mechanism paper was later retracted, and an earlier foundational Dihexa paper received a formal notice of concern. That does not prove every idea about Dihexa is false, but it sharply lowers confidence in strong claims. How to read this: Read this one with more skepticism than usual. Mechanism, dosing, half-life, human safety, and long-term risk are not established. Treat vendor claims of precise dosing, long duration, or guaranteed cognitive enhancement as unsupported unless they cite human PK and controlled human outcome data.
- Dihexa, also called PNB-0408, is a synthetic angiotensin IV analog.
- Chemically, it is a small modified oligopeptide described as N-hexanoyl-Tyr-Ile-(6) aminohexanoic amide.
- It was designed to overcome the usual weaknesses of short peptides: rapid degradation, poor oral exposure, and limited blood-brain barrier penetration.
- In practical terms, it sits between peptide pharmacology and small-molecule nootropic research rather than behaving like a standard hormone peptide.
- The intended therapeutic concept was neurorepair: use a stable AngIV-derived scaffold to support synapse formation and memory processes.
- That concept remains investigational. Dihexa is not FDA-approved, has no labeled human indication, and does not belong with clinically used neuroactive drugs such as prescription stimulants, cholinesterase inhibitors, or approved dementia therapies.
- Dihexa is an angiotensin-IV-derived nootropic research compound often discussed for synaptogenesis. It is distinct from ordinary peptides because it is designed for CNS penetration and strong trophic signaling hypotheses.
- The proposed mechanism is positive modulation of the hepatocyte growth factor / MET receptor system, often written HGF/c-Met or HGF/MET.
- HGF and MET are involved in cell survival, migration, tissue remodeling, neurodevelopment, and synaptic plasticity.
- Dihexa was proposed to bind or stabilize HGF in a way that enhances MET activation when HGF is present.
- This mechanism must be framed cautiously.
- The paper most often cited for the HGF/c-Met mechanism was retracted in 2025, and an earlier Dihexa paper received a formal notice of concern.
- A safer phrasing is: Dihexa has been proposed to interact with HGF/MET signaling, and later animal studies have explored related neuroplasticity pathways, but the specific mechanism is not settled enough to treat as proven.
- Once you're past the basics, the safety tension is obvious: the same pathway discussed for neuronal repair is also a major pathway in cancer biology.
- HGF/MET signaling participates in proliferation, migration, invasion, angiogenesis, and metastasis in many tumors.
- That does not mean Dihexa causes cancer, but it does mean arbitrary long-term HGF/MET potentiation without human toxicology is not a trivial risk.
- The main mechanism claim involves HGF/c-Met pathway modulation and synaptogenic signaling. Because c-Met biology is also relevant to cancer and tissue growth, mechanism language needs a benefit-risk boundary. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Preclinical cognition models: The original rat work reported that Dihexa and related metabolically stabilized AngIV analogs improved performance in scopolamine-impaired and aged rats, including Morris water maze outcomes. That paper is historically important but carries an expression-of-concern notice, so the guide treats it as hypothesis-generating rather than reliable proof.
- HGF/MET synaptogenesis claims: A follow-up paper reported that Dihexa promoted hippocampal spinogenesis and synaptogenesis through HGF/c-Met signaling. That paper is now retracted. A statement such as “Dihexa is 10 million times stronger than BDNF” does not hold up, because the underlying comparison came from cell-culture claims, not clinical outcomes, and the mechanistic evidence base is compromised.
- Independent animal work: A 2021 APP/PS1 mouse study reported that intragastric Dihexa improved spatial-learning measures and increased synaptic and neuronal markers while affecting PI3K/AKT signaling. A 2025 repeated mild traumatic brain injury rat study also used Dihexa as an HGF/MET-positive modulator and reported rescue of working-memory deficits. These are useful preclinical signals, but neither establishes human efficacy, human safety, optimal route, or dose.
- Human evidence gap: No controlled human clinical trial evidence was found for Dihexa itself. There is also no published human dose-ranging, adverse-event, or pharmacokinetic program adequate for clinical risk assessment. For a beginner, this is the most important sentence in the entry.
- The most striking claims come from preclinical cognitive models, not robust human trials. It is useful to explain why researchers are interested while clearly stating that human efficacy and long-term safety are unproven. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Preclinical oral rat dose reported in evidence review [Animal/Preclinical]; Route: Oral; Dose: 2 mg/kg; Frequency: Reported in rats; Schedule varies by study; Duration: Preclinical study context; Status: No - animal/preclinical only; Not FDA-approved for human use.
- Protocol 2: Community/clinic oral capsule range [Community/Biohacker/Anecdotal]; Route: Oral capsule; Dose: 5 mg – 20 mg; Frequency: Often once daily or divided depending on clinic/community protocol; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Commercial clinic 10 mg oral capsule listing [Community/Biohacker/Anecdotal]; Route: Oral capsule; Dose: 10 mg; Frequency: Once daily; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 4: Reddit nootropic ramp anecdote [Community/Biohacker/Anecdotal]; Route: Sublingual; Dose: About 5 mg; Frequency: 2–3 times daily; Timing: User-reported; Stacked with other nootropics in anecdote; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 5: Speculative online subcutaneous exposure calculation [Community/Biohacker/Anecdotal]; Route: Subcutaneous (speculative); Dose: Approx. 0.02 mg – 0.3 mg estimated systemic-equivalent range; Frequency: Not standardized; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Community topical, oral, and injectable reports exist, but route efficacy is not established. The protocol rows are anecdotal/research-market, not clinical dosing. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable.
- Half-life basis: no validated human elimination half-life or route-specific human PK dataset was found. Preclinical descriptions call Dihexa orally active and blood-brain-barrier permeable, but that does not provide a human half-life.
- Beginner translation: A missing steady-state estimate is not an oversight. It is the honest answer when human half-life is unavailable. Any precise claim such as “steady state in X days” would be false precision unless backed by route-specific human PK.Practical interpretation: For Dihexa, effect-duration claims are pharmacodynamic speculation. Cognitive or mood changes, if reported, do not prove plasma steady state or CNS accumulation. What is known from the public literature is qualitative rather than quantitative: Dihexa was designed to be more metabolically stable and more CNS-penetrant than native AngIV. What is not established is the human absorption fraction, Tmax, Cmax, half-life, active metabolites, CNS exposure, washout time, or accumulation pattern.
- CNS exposure and duration are central unknowns. Without human PK/PD, calculators cannot responsibly predict steady-state cognitive effects or risk windows. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- No evidence-based stacking protocol exists.
- Dihexa is often discussed alongside Semax, Selank, Cerebrolysin, NAD+, or mitochondrial peptides, but those stacks are community inventions unless tested directly.
- Combining multiple neuroactive agents also makes it harder to interpret anxiety, insomnia, irritability, headaches, mood elevation, or cognitive changes.
- Intermediate caution: Avoid stacking Dihexa with other growth-factor, angiogenic, neurotrophic, or cancer-biology-adjacent agents unless a clinician or formal protocol has a clear reason.
- The mechanistic overlap may be more important than the names of the products.
- Dihexa is sometimes stacked with racetams, cholinergics, semax-family peptides, or NAD/mitochondrial compounds. Avoid stacking multiple cognitive agents initially because anxiety, insomnia, headache, or mood changes become difficult to attribute. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Human safety is unknown.
- There is no adequate public human toxicology package, no published long-term safety study, and no validated adverse-event profile.
- That means mild self-reported side effects cannot be used to conclude that the compound is safe.
- Theoretical concerns include tumor biology through HGF/MET signaling, unpredictable neuropsychiatric effects, seizure-threshold uncertainty, unknown drug-drug interactions, and unknown effects in pregnancy, breastfeeding, adolescents, and people with neurologic or psychiatric conditions.
- Contraindication-style cautions: active cancer, history of aggressive cancer, unexplained masses, premalignant lesions under evaluation, severe psychiatric instability, seizure disorder, pregnancy or breastfeeding, and use in minors are high-risk or inappropriate without formal medical oversight.
- Theoretical c-Met/pro-growth signaling is the main long-term concern, alongside unknown neuropsychiatric effects. A lack of adverse reports does not mean low risk. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- There is no validated monitoring panel for Dihexa.
- Routine labs can miss the main theoretical risks because HGF/MET signaling risk is not captured by a simple CMP, CBC, or inflammatory marker panel.
- If a research setting is evaluating Dihexa, useful monitoring would include objective cognitive testing, sleep tracking, mood/irritability screening, headache or neurologic symptom logs, and careful documentation of route, formulation, and batch.
- For any person with cancer history or suspicious lesions, medical evaluation matters more than self-monitoring.
- Track sleep, anxiety, headaches, mood lability, blood pressure if stimulant-like effects appear, cognition tasks, and any unusual growth/tumor-history concern. Subjective mental sharpness alone is not enough. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Not approved for any human indication. No labeled prescription product exists. Research-use-only sales do not make it legal or validated for human use.
- Compounding: Dihexa is not an FDA-approved drug and is not part of a standard regulated peptide-compounding pathway. Any clinic or vendor presenting it as routine therapy owes you human safety data, legal basis, and source-quality documentation.
- Anti-doping: Competitive athletes should treat Dihexa as high risk under WADA S0 principles because it is not an approved therapeutic substance for human use and is marketed for biologic effects. Athletes should verify with their anti-doping organization before any exposure.
- Dihexa is a research compound, not an FDA-approved cognitive therapy. FDA has included Dihexa acetate in peptide safety/compounding discussions, but review is not approval. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.